Skip to main content

Table 1 Clinical characteristics for PCI and medical group in very elderly female ACS patients

From: Improvement of long-term clinical outcomes by successful PCI in the very elderly women with ACS

Variables

Before PS match

P value

After PS match

P value

PCI group (n = 232)

Medical group (n = 497)

PCI group (n = 129)

Medical group (n = 129)

Demographic

 Age (years)

82 (81, 84)

82 (81, 85)

0.082

82 (81, 84)

82 (81, 85)

0.273

 BMI (kg/m2)

24.4 (22.3, 27.0)

24.4 (22.0, 26.9

0.6

24.4 (22.6, 27.3)

24.0 (21.9, 27.3)

0.327

Initial presentation

 Heart rate (beats/min)

70 (65, 79)

70 (63, 81)

0.961

70 (64, 76)

72 (65, 84)

0.057

 Systolic BP (mmHg)

134 (120, 149)

133 (122, 147)

0.782

135 (124, 149)

130 (120, 148)

0.168

 Diastolic BP (mmHg)

70 (62, 79)

70 (64, 80)

0.371

70 (63, 77)

70 (64, 80)

0.733

Past medical history

 Hypertension, n (%)

185 (79.9)

422 (84.9)

0.082

102 (79.1)

108 (83.7)

0.337

 Diabetes mellitus, n (%)

92 (39.7)

175 (35.2)

0.246

48 (37.2)

49 (38.0)

0.898

 Dyslipidemia, n (%)

96 (41.4)

216 (43.5)

0.597

54 (41.9)

44 (34.1)

0.20

 Prior MI, n (%)

17 (7.3)

51 (10.3)

0.202

9 (7.0)

9 (7.0)

0.986

 Prior stroke, n (%)

56 (24.1)

137 (27.6)

0.329

30 (23.3)

31 (24.0)

0.884

 Smoking, n (%)

23 (9.9)

29 (5.8)

0.046

8 (6.2)

10 (7.8)

0.625

 Prior PAD, n (%)

2 (1.0)

3 (0.7)

0.688

0 (0)

3 (2.4)

0.247

Clinical diagnosis

 UAP, n (%)

111 (47.8)

343 (69.0)

< 0.001

66 (51.2)

58 (45.0)

0.319

 NSTEMI, n (%)

55 (23.7)

104 (20.9)

0.397

41 (31.8)

42 (32.6)

0.894

 STEMI, n (%)

66 (28.4)

50 (10.1)

< 0.001

22 (17.1)

29 (22.5)

0.274

 Length of stay (days)

7 (6, 10)

7 (6, 10)

0.461

7 (6, 10)

8 (6, 11)

0.173

Laboratory finding

 HbA1c (%)

6.2 (5.7, 7.2)

6.1 (5.7, 6.9)

0.30

6.3 (5.7, 7.2)

6.2 (5.7, 7.0)

0.753

 TC (mmol/L)

4.41 (3.69, 5.26)

4.26 (3.60, 5.02)

0.087

4.4 (3.70, 5.1)

4.3 (3.6, 5.2)

0.683

 LDL-C (mmol/L)

2.46 (1.99, 3.03)

2.34 (1.81, 2.89)

0.012

2.49 (1.96, 2.99)

2.43 (1.91, 2.97)

0.510

 TG (mmol/L)

1.32 (0.96, 1.85)

1.24 (0.90, 1.67)

0.052

1.32 (0.98, 1.84)

1.22 (0.89, 1.67)

0.183

 Creatinine (umol/L)

76.3 (65.9, 91.7)

79.5 (67.9, 100.2)

0.016

79 (66.6, 95.7)

81.6 (68.4, 99.1)

0.299

 ALT (U/L)

15 (10, 21.8)

13 (10, 20)

0.024

15 (11, 21)

14 (10, 22)

0.586

 CK-MB (ng/ml)

1.7 (1.1, 4.05)

1.4 (0.9, 2.53)

0.002

1.7 (1.1, 4.5)

1.8 (1.08, 5.95)

0.553

 log NT-proBNP

2.93 (2.56, 3.42)

3.05 (2.49, 3.58)

0.231

2.92 (2.56, 3.45)

3.34 (2.86, 3.82)

< 0.001

 LVEF ≥ 50%, n (%)

197 (87.2)

414 (87.3)

0.949

111 (86.7)

102 (82.3)

0.328

  1. *P2Y12 receptor antagonist within 12 months after PCI. P, level of statistical significance
  2. BMI body mass index, BP blood pressure, MI myocardial infarction, PAD peripheral artery disease, UAP unstable angina pectoris, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-elevation myocardial infarction, HbA1c Hemoglobin A1c, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, ALT alanine aminotransferase, CK-MB creatine kinase-MB, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers